ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15 nov. 2022 04h00 HE | AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors  - Potential as mono- and combination therapy for...
Cancer Gene Therapy Market Report 2022: High Growth in the Pharmaceutical Industry Driving Sector
14 nov. 2022 08h21 HE | Research and Markets
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market Size, Share & Trends Analysis Report by Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), by...
PDS Biotech Logo.png
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 07h30 HE | PDS Biotechnology Corporation
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC...
PDS Biotech Logo.png
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
14 nov. 2022 07h00 HE | PDS Biotechnology Corporation
In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation)89% (8/9) had no...
BiondVax LOGO.png
BiondVax Announces Plan to Implement ADS Ratio Change
10 nov. 2022 16h00 HE | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
Adagene_Logo_GNW.png
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
10 nov. 2022 09h05 HE | Adagene Inc.
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy - - Results...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10 nov. 2022 09h00 HE | EvolveImmune
Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of...
EVAXION_BLACK_RGB.jpg
Evaxion CEO comments on strategic focus
10 nov. 2022 04h10 HE | Evaxion Biotech
COPENHAGEN, Denmark, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Affimed Logo.jpg
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
07 nov. 2022 08h05 HE | Affimed N.V.
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 oct. 2022 17h49 HE | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...